News Industry News New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes September 15, 2017
News Industry News New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control March 01, 2016
News Industry News New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events September 08, 2015
News Industry News New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets June 19, 2015